PfizerMEX:PFE +2.21%67 Days Payable is 125.23 as of Mar. 2026, which is 0% above its 10-year median of 124.85. GuruFocus rates MEX:PFE with a GF Score™ of 67/100 and a GF Value™ of MXN453.82 (Fairly Valued). The stock has 5 warning signs investors should review. Among 923 Drug Manufacturers companies, Pfizer ranks better than 61.32% on this metric.
Pfizer's average Accounts Payable for the
three
months ended in Mar. 2026 was MXN87,803 Mil. Pfizer's Cost of Goods Sold for the
three
months ended in Mar. 2026 was MXN63,980 Mil.
Hence, Pfizer's Days Payable for the
three
months ended in Mar. 2026 was 125.23.
The historical rank and industry rank for Pfizer's Days Payable or its related term are showing as below:
MEX:PFE'
s Days Payable Range Over the Past 10 Years
Min: 58.39 Med: 124.85 Max: 193.99
Current: 109.59
During the past 13 years, Pfizer's highest Days Payable was 193.99. The lowest was 58.39. And the median was 124.85.
MEX:PFE's Days Payable is ranked better than 61.32% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs MEX:PFE: 109.59
Pfizer's Days Payable
declined
from Mar. 2025 (176.12) to Mar. 2026 (125.23).
It may suggest that Pfizeraccelerated paying its suppliers.
Pfizer Days Payable Related Terms
Pfizer Days Payable Historical Data
* Premium members only.
The historical data trend for Pfizer's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PFE vs GILD, BMY, AMGN: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Pfizer's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pfizer Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pfizer's Days Payable distribution charts can be found below:
* The bar in red indicates where Pfizer's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pfizer's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pfizer (MEX:PFE) has a Days Payable of 125.23 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pfizer and its competitors. This is near median its historical median of 124.85. Over the past decade, Pfizer's Days Payable has ranged from 58.39 to 193.99. According to the industry distribution chart, Pfizer ranks #357 out of 923 companies in the Drug Manufacturers industry, placing it in the top 38.7%.
Is Pfizer's Days Payable too high?
Pfizer's current Days Payable of 125.23 is near median its 10-year median of 124.85. Over the past 10 years, this metric has ranged from a low of 58.39 to a high of 193.99. The Drug Manufacturers industry median Days Payable is 90.98. Pfizer's value of 125.23 is 37.6% above this industry median. Based on the distribution chart, Pfizer ranks #357 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Pfizer has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Days Payable compare to GILD and BMY?
According to the Drug Manufacturers industry distribution chart, Pfizer ranks #357 out of 923 companies for Days Payable. This puts Pfizer in the upper half of its industry. The industry median Days Payable is 90.98. Pfizer's value of 125.23 is 37.6% above this benchmark. Historically, Pfizer's own Days Payable has ranged from 58.39 to 193.99 over the past decade. While the company's 10-year median is 124.85 vs. the industry median of 90.98, Pfizer has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pfizer's current Days Payable of 125.23 is 37.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pfizer and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pfizer's current Days Payable is 125.23, which is near median its own 10-year median of 124.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (MEX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is MXN453.82, compared to a current price of MXN423.00 — trading 6.8% below its estimated fair value. The current Days Payable is 125.23, which is near median its 10-year median of 124.85 and 37.6% above the Drug Manufacturers industry median of 90.98. Pfizer's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pfizer (MEX:PFE), the current Days Payable is 125.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pfizer (MEX:PFE) Overvalued in 2026?
Based on GuruFocus' analysis, Pfizer stock appears to be undervalued.
The current stock price of MXN423.00 is trading 6.8% below its estimated GF Value™ of MXN453.82.
GuruFocus considers Pfizer to be Fairly Valued.
Key valuation signals for MEX:PFE:
Days Payable: 125.23 (near median its 10-year median of 124.85)
GF Value™: MXN453.82 vs. price of MXN423.00 (6.8% below fair value)
Industry Position: 37.6% above the Drug Manufacturers median (#357 of 923)
No single metric tells the full story. See the MEX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
67GF Score
Get the complete analysis for MEX:PFE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PFE has been successfully added to your 
